Northern Trust
INDP icon

Northern Trust’s Indaptus Therapeutics INDP Stock Holding History

Northern Trust’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-461
Closed -$24.7K – 4496
2023
Q2 		$24.7K Hold
461
– – ﹤0.01% 4370
2023
Q1 		$23.9K Hold
461
– – ﹤0.01% 4418
2022
Q4 		$18.7K Hold
461
– – ﹤0.01% 4504
2022
Q3 		$28K Buy
461
+93
+25% +$7.25K ﹤0.01% 4478
2022
Q2 		$27K Hold
368
– – ﹤0.01% 4573
2022
Q1 		$41K Buy
+368
New +$47.2K ﹤0.01% 4575

Other funds holding INDP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's INDP Position: Q3 2023 in Review

Northern Trust sold out of Indaptus Therapeutics (INDP) in Q3 2023, closing a stake of 461 shares — an estimated $24.7K sold.

Northern Trust first reported a position in INDP in Q1 2022 and held it in 6 quarters. The position peaked at $41K in Q1 2022. 13 funds tracked by Wall St. Rank hold INDP as of Q3 2023.

  • Northern Trust reported no remaining Indaptus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Northern Trust sold 461 Indaptus Therapeutics shares in Q3 2023, an estimated $24.7K.
  • Northern Trust first reported a position in Indaptus Therapeutics in Q1 2022 and held it in 6 quarters.
  • Northern Trust's Indaptus Therapeutics position peaked at $41K in Q1 2022.
  • 13 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.